Quartz 4

Medications Overview

6 min read

Medications Overview

This is a mechanistic overview — how each drug class works at the biochemical level and what it actually targets. Not dosing advice.

Strategy: Block Receptors vs. Prevent Release vs. Block Synthesis

Interventions for MCAS and Histamine Intolerance fall into three broad categories:

  1. Receptor blockers — the mediator is still released, but its target receptor is occupied by a competing molecule. Symptoms are reduced but the underlying activation continues. (H1 Antihistamines, H2 Antihistamines, Montelukast)

  2. Mast cell stabilizers — the cell is prevented from degranulating in the first place. The mediators stay inside the cell. This addresses the source. (Cromolyn Sodium, Ketotifen, and to a lesser extent quercetin)

  3. Synthesis inhibitors — the cell can’t produce certain mediators even if activated. (Montelukast partially, aspirin in aspirin-tolerant patients by blocking prostaglandin synthesis)

In practice, most patients need a combination across categories because no single drug covers all mediators and pathways.

H1 Antihistamines

See H1 Antihistamines for full detail. Summary:

These compete with Histamine for H1 Receptor binding. When cetirizine occupies the H1 receptor, histamine can’t bind → the downstream vasodilation, permeability increase, bronchoconstriction, and itch signaling are blocked.

First generation (diphenhydramine, hydroxyzine, chlorpheniramine): Cross the blood-brain barrier → sedation. This is a feature at bedtime (see Sleep and Histamine) and a bug during the day.

Second generation (cetirizine, loratadine, fexofenadine): Designed to have poor BBB penetration → less sedation. Cetirizine is mildly sedating in some people; fexofenadine is the least sedating.

H1 blockers address only H1-mediated symptoms. They don’t touch gastric acid (H2 Receptor), Prostaglandins, Leukotrienes, or Cytokines.

H2 Antihistamines

See H2 Antihistamines for full detail. Summary:

Famotidine (most commonly used), ranitidine (withdrawn from many markets due to NDMA contamination concerns), cimetidine.

These compete with Histamine at H2 receptors. H2 receptors are primarily on gastric parietal cells (acid secretion), cardiac muscle (heart rate), and some immune cells.

H1 + H2 blockade together is more effective than either alone because they’re covering different receptor populations. A patient on cetirizine + famotidine has both major histamine receptor pathways partially blocked.

Mast Cell Stabilizers

See Mast Cell Stabilizers and individual drug notes for detail.

Cromolyn Sodium: Stabilizes the mast cell membrane, preventing Degranulation. The exact molecular mechanism is not fully characterized, but it appears to block calcium influx through ion channels, preventing the calcium-dependent signaling cascade that triggers granule fusion. Poorly absorbed orally — oral formulation acts locally in the gut. Must be taken consistently (not PRN) because it prevents activation rather than blocking mediators already released.

Ketotifen: Has dual action — mast cell stabilization + H1 antihistamine properties. Crosses the blood-brain barrier → can be sedating. Available orally and as eye drops. Often used when both stabilization and antihistamine effects are needed.

Quercetin: A plant flavonoid with demonstrated mast cell stabilizing properties in vitro. Inhibits calcium influx and reduces histamine release from mast cells. Bioavailability is the main limitation — absorption from the gut is relatively poor, though some formulations (phytosomal quercetin) have improved this. See Mast Cell Stabilizers.

Leukotriene Inhibitors

See Montelukast for detail.

Montelukast blocks the CysLT1 receptor — the receptor for cysteinyl Leukotrienes (LTC4, LTD4, LTE4). It does not block Histamine at all. It targets the Arachidonic Acid pathway’s 5-LOX branch.

This matters because leukotrienes are 100-1000x more potent than histamine at causing bronchoconstriction and are significant drivers of vascular permeability. A patient who doesn’t respond adequately to H1 + H2 blockade may have significant leukotriene-mediated symptoms that require a separate intervention.

Particularly relevant for people with salicylate sensitivity, where COX inhibition shunts more arachidonic acid toward leukotriene production.

Montelukast neuropsychiatric effects

Montelukast carries an FDA black box warning for neuropsychiatric side effects including agitation, depression, suicidal ideation, and vivid dreams. The mechanism for these effects is not fully understood. Monitoring is appropriate, and the drug should be discontinued if neuropsychiatric symptoms emerge. For some patients the benefits outweigh this risk; for others it’s not tolerable.

Low Dose Naltrexone (LDN)

See Low Dose Naltrexone for detail.

Naltrexone at standard doses (50mg) is an opioid antagonist used for addiction. At low doses (1-4.5mg), the proposed mechanism is different: brief opioid receptor blockade triggers a compensatory upregulation of endogenous endorphins and enkephalins, which then have immunomodulatory effects — including modulation of microglial activation and possibly mast cell behavior.

Evidence status

LDN has a dedicated following among patients with MCAS, chronic pain, and autoimmune conditions. Clinical evidence consists primarily of case series, small trials, and observational studies. Large randomized controlled trials for MCAS specifically are lacking. It appears to help some patients meaningfully. The evidence base is not strong enough to draw firm conclusions about efficacy or mechanism. It has a generally favorable safety profile at low doses.

DAO Supplementation

See DAO Supplements. Oral DAO (diamine oxidase enzyme derived from porcine kidneys) is taken with meals to supplement the body’s own DAO in the gut lumen. It adds enzyme capacity to break down Dietary Histamine before absorption.

Limitations: the enzyme is a protein and is partially degraded by stomach acid and digestive proteases. Enteric-coated formulations help. It addresses dietary histamine only — not endogenous histamine from mast cells, not non-histamine mediators. Most useful when Histamine Intolerance is a significant component.

Hormonal Interventions

Covered in detail at Estrogen and Mast Cells.

Progesterone supplementation: May provide mast cell stabilizing effect (see Progesterone and Mast Cells). Relevant in perimenopause where progesterone loss unmasks or worsens MCAS.

HRT (hormone replacement therapy): Complex. Estrogen component could worsen mast cell activation; progesterone component could help. Route of administration (transdermal vs. oral) and formulation (bioidentical vs. synthetic) may affect mast cell impact. Requires a provider who understands both hormonal management and mast cell biology.

Lifestyle Interventions (With Biochemical Rationale)

These are not “wellness tips.” Each targets a specific mechanism:

Graph View

Backlinks